Emergence of Ocular Toxicities Associated with Novel Anticancer Therapeutics: What the Oncologist Needs to Know
Cette étude passe en revue les toxicités oculaires (mécanismes, fréquence, sévérité, prise en charge) liées aux thérapies ciblées chez les patients atteints d'un cancer
As cancer treatment evolves in the era of precision oncology, molecularly targeted agents (MTAs) have become frontline therapy for many cancers. MTAs are biologicallytargeted and thought to have less off-target toxicity; however, the eye is particularly susceptible to off-target toxicities given its unique microenvironment. In this review,we present commonly used FDA-approved MTAs, any associated ocular toxicities and reviewt he mechanisms, frequency, severity, and management. Increased awareness and communicationbetween clinicians caring for cancer patients is needed for individualized risk assessment,earlier diagnosis, and mitigation of ocular toxicities.